SEARCH

SEARCH BY CITATION

References

  • 1
    Desvarieux M, Demmer RT, Rundek T, Boden-Albala B, Jacobs DR, Jr., Sacco RL, Papapanou PN. Periodontal micro-biota and carotid intima-media thickness: the oral infections and vascular disease epidemiology study (INVEST). Circulation. 2005; 111: 57682.
  • 2
    Spahr A, Klein E, Khuseyinova N, Boeckh C, Muche R, Kunze M, Rothenbacher D, Pezeshki G, Hoffmeister A, Koenig W. Periodontal infections and coronary heart disease: role of periodontal bacteria and importance of total pathogen burden in the Coronary Event and Periodontal Disease (CORODONT) study. Arch Intern Med. 2006; 166: 5549.
  • 3
    Pussinen PJ, Mattila K. Periodontal infections and atherosclerosis: mere associations Curr Opin Lipidol. 2004; 15: 5838.
  • 4
    Saikku P, Leinonen M, Tenkanen L, Linnanmaki E, Ekman MR, Manninen V, Manttari M, Frick MH, Huttunen JK. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 1992; 116: 2738.
  • 5
    Etminan M, Carleton B, Delaney JA, Padwal R. Macrolide therapy for Chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials. Pharmacotherapy. 2004; 24: 33843.
  • 6
    Scannapieco FA, Bush RB, Paju S. Associations between periodontal disease and risk for nosocomial bacterial pneumonia and chronic obstructive pulmonary disease. A systematic review. Ann Periodontol. 2003; 8: 5469.
  • 7
    Lehtiniemi J, Karhunen PJ, Goebeler S, Nikkari S, Nikkari ST. Identification of different bacterial DNAs in human coronary arteries. Eur J Clin Invest. 2005; 35: 136.
  • 8
    Ott SJ, El Mokhtari NE, Musfeldt M, Hellmig S, Freitag S, Rehman A, Kuhbacher T, Nikolaus S, Namsolleck P, Blaut M, Hampe J, Sahly H, Reinecke A, Haake N, Gunther R, Kruger D, Lins M, Herrmann G, Folsch UR, Simon R, Schreiber S. Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease. Circulation. 2006; 113: 92937.
  • 9
    Haraszthy VI, Zambon JJ, Trevisan M, Zeid M, Genco RJ. Identification of periodontal pathogens in atheromatous plaques. J Periodontol. 2000; 71: 155460.
  • 10
    Engelmann MG, Redl CV, Pelisek J, Barz C, Heesemann J, Nikol S. Chronic perivascular inoculation with Chlamydophila pneumoniae results in plaque formation in vivo. Lab Invest. 2006; 86: 46776.
  • 11
    Tuomainen AM, Jauhiainen M, Kovanen PT, Metso J, Paju S, Pussinen PJ. Aggregatibacter actinomycetemcomitans induces MMP-9 expression and proatherogenic lipoprotein profile in apoE-deficient mice. Microb Pathog. 2008; 44: 1117.
  • 12
    Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol. 2005; 6: 13542.
  • 13
    Marshall JS. Mast-cell responses to pathogens. Nat Rev Immunol. 2004; 4: 78799.
  • 14
    Galli SJ, Maurer M, Lantz CS. Mast cells as sentinels of innate immunity. Curr Opin Immunol. 1999; 11: 539.
  • 15
    Genovese A, Bouvet J P, Florio G, Lamparter-Schummert B, Bjorck L, Marone G. Bacterial immunoglobulin superantigen proteins A and L activate human heart mast cells by interacting with immunoglobulin E. Infect Immun. 2000; 68: 551724.
  • 16
    Shin JS, Gao Z, Abraham SN. Involvement of cellular caveolae in bacterial entry into mast cells. Science. 2000; 289: 7858.
  • 17
    Xu X, Zhang D, Lyubynska N, Wolters PJ, Killeen NP, Baluk P, McDonald DM, Hawgood S, Caughey GH. Mast cells protect mice from Mycoplasma pneumonia. Am J Respir Crit Care Med. 2006; 173: 21925.
  • 18
    Echtenacher B, Mannel DN, Hultner L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature. 1996; 381: 757.
  • 19
    Malaviya R, Ikeda T, Ross E, Abraham SN. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature. 1996; 381: 7780.
  • 20
    Sun J, Sukhova GK, Wolters PJ, Yang M, Kitamoto S, Libby P, MacFarlane LA, Mallen-St Clair J, Shi G P. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med. 2007; 13: 71924.
  • 21
    Kaartinen M, Penttila A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation. 1994; 90: 166978.
  • 22
    Lindstedt KA, Kovanen PT. Mast cells in vulnerable coronary plaques: potential mechanisms linking mast cell activation to plaque erosion and rupture. Curr Opin Lipidol. 2004; 15: 56773.
  • 23
    Bot I, De Jager SC, Zernecke A, Lindstedt KA, Van Berkel TJ, Weber C, Biessen EA. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation. 2007; 115: 251625.
  • 24
    Ali AS, Lax AS, Liljestrom M, Paakkari I, Ashammakhi N, Kovanen PT, Konttinen YT. Mast cells in atherosclerosis as a source of the cytokine RANKL. Clin Chem Lab Med. 2006; 44: 6724.
  • 25
    Kaartinen M, Penttila A, Kovanen PT. Mast cells in rupture-prone areas of human coronary atheromas produce and store TNF-alpha. Circulation. 1996; 94: 278792.
  • 26
    Smith JD, Breslow JL. The emergence of mouse models of atherosclerosis and their relevance to clinical research. J Intern Med. 1997; 242: 99109.
  • 27
    Lappalainen J, Lindstedt KA, Kovanen PT. A protocol for generating high numbers of mature and functional human mast cells from peripheral blood. Clin Exp Allergy. 2007; 37: 140414.
  • 28
    Hakala JK, Oksjoki R, Laine P, Du H, Grabowski GA, Kovanen PT, Pentikainen MO. Lysosomal enzymes are released from cultured human macrophages, hydrolyze LDL in vitro, and are present extracellularly in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2003; 23: 14306.
  • 29
    Caldwell HD, Kromhout J, Schachter J. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect Immun. 1981; 31: 116176.
  • 30
    Slots J. Selective medium for isolation of Actinobacillus actinomycetemcomitans. J Clin Microbiol. 1982; 15: 6069.
  • 31
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25: 4028.
  • 32
    Tormakangas L, Alakarppa H, David DB, Leinonen M, Saikku P. Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice. Antimicrob Agents Chemother. 2004; 48: 365561.
  • 33
    Mamata Y, Hakki A, Newton C, Burdash N, Klein TW, Friedman H. Differential effects of Chlamydia pneumoniae infection on cytokine levels in human T lymphocyte- and monocyte-derived cell cultures. Int J Med Microbiol. 2007; 297: 10915.
  • 34
    Tiirola T, Sinisalo J, Nieminen MS, Silvennoinen-Kassinen S, Paldanius M, Saikku P, Jauhiainen M, Leinonen M. Chlamydial lipopolysaccharide is present in serum during acute coronary syndrome and correlates with CRP levels. Atherosclerosis. 2007; 194: 4037.
  • 35
    Tuomainen AM, Jauhiainen M, Kovanen PT, Metso J, Paju S, Pussinen PJ. Aggregatibacter actinomycetemcomitans induces MMP-9 expression and proatherogenic lipoprotein profile in apoE-deficient mice. Microb Pathog. 2008; 44: 1117.
  • 36
    Aalto-Setala K, Laitinen K, Erkkila L, Leinonen M, Jauhiainen M, Ehnholm C, Tamminen M, Puolakkainen M, Penttila I, Saikku P. Chlamydia pneumoniae does not increase atherosclerosis in the aortic root of apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2001; 21: 57884.
  • 37
    Paju S, Pussinen PJ, Sinisalo J, Mattila K, Dogan B, Ahlberg J, Valtonen V, Nieminen MS, Asikainen S. Clarithromycin reduces recurrent cardiovascular events in subjects without periodontitis. Atherosclerosis. 2006; 188: 4129.
  • 38
    Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997; 96: 4047.
  • 39
    Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J. 1999; 20: 1217.
  • 40
    O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, Benner RJ, Fisher MR, Cook TD. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA. 2003; 290: 145966.
  • 41
    Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005; 352: 208.
  • 42
    Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, Rogers WJ, Crouse JR, Borrowdale SL, Schron E, Knirsch C. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005; 352: 163745.
  • 43
    Paju S, Sinisalo J, Pussinen PJ, Valtonen V, Nieminen MS. Is periodontal infection behind the failure of antibiotics to prevent coronary events Atherosclerosis. 2007; 193: 1935.
  • 44
    Vink A, Schoneveld AH, Van Der Meer JJ, Van Middelaar BJ, Sluijter J P, Smeets MB, Quax PH, Lim SK, Borst C, Pasterkamp G, De Kleijn DP. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation. 2002; 106: 198590.
  • 45
    Schoneveld AH, Oude Nijhuis MM, Van Middelaar B, Laman JD, De Kleijn DP, Pasterkamp G. Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development. Cardiovasc Res. 2005; 66: 1629.
  • 46
    Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M. Lack of Tolllike receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA. 2004; 101: 1067984.
  • 47
    Chi H, Barry SP, Roth RJ, Wu JJ, Jones EA, Bennett AM, Flavell RA. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci USA. 2006; 103: 22749.
  • 48
    Yoshioka M, Fukuishi N, Iriguchi S, Ohsaki K, Yamanobe H, Inukai A, Kurihara D, Imajo N, Yasui Y, Matsui N, Tsujita T, Ishii A, Seya T, Takahama M, Akagi M. Lipoteichoic acid downregulates FcepsilonRI expression on human mast cells through Toll-like receptor 2. J Allergy Clin Immunol. 2007; 120: 45261.
  • 49
    Kubo Y, Fukuishi N, Yoshioka M, Kawasoe Y, Iriguchi S, Imajo N, Yasui Y, Matsui N, Akagi M. Bacterial components regulate the expression of Toll-like receptor 4 on human mast cells. Inflamm Res. 2007; 56: 705.